VG Life Sciences (VGLS) SEC Filings

VG Life Sciences, Inc. filed a Form 10 to register under the Securities Exchange Act of 1934 pursuant to Section 12(g) and to become a reporting company.

The company describes itself as a shell with no ongoing operations or revenue, no cash on hand and a working capital deficit of $3,393,105 as of September 30, 2025. Management seeks to identify and acquire an operating business; there are no target negotiations underway. Auditors have expressed substantial doubt about the company’s ability to continue as a going concern. Recent operating results show net losses, including a $170,823 loss for the three months ended September 30, 2025 and a nine-month net loss of $554,904.